Processa Pharmaceuticals, Inc. Payments to Acquire Restricted Certificates of Deposit
Processa Pharmaceuticals, Inc. (PCSA) reported Payments to Acquire Restricted Certificates of Deposit of $496.00 thousand for the 6-month period ending 2018-06-30, per its 10-Q filed 2019-08-14.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireRestrictedCertificatesOfDeposit · last filed 2019-08-14
- Processa Pharmaceuticals, Inc. payments to acquire restricted certificates of deposit for fiscal 2017 was -$1.02M, a 200.00% decline from fiscal 2016.
- Processa Pharmaceuticals, Inc. payments to acquire restricted certificates of deposit for fiscal 2016 was $1.02M.
| Period end | Payments to Acquire Restricted Certificates of Deposit 6 month | Payments to Acquire Restricted Certificates of Deposit 12 month |
|---|---|---|
| 2018-06-30 | $496.00K 10-Q · filed 2019-08-14 | |
| 2017-12-31 | -$1.02M 10-K · filed 2018-04-16 | |
| 2016-12-31 | $1.02M 10-K · filed 2018-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |